InMed and the laboratory of Dr. Vikramaditya Yadav at the University of British Columbia collaborate on a proprietary biosynthesis technology to produce bioidentical, high purity, high grade cannabinoids. The host selected is E.coli. In this video, Dr. Yadav talks how an E.coli-based system is uniquely suited for producing cannabinoids.
Epidermolysis Bullosa News: INM-755 Found Safe in 5 Adults With EB, Trial Opens to Adolescents
Epidermolysis Bullosa News writes about InMed’s Phase 2 clinical trial of INM-755 cannabinol cream, an investigational new treatment for epidermolysis bullosa. Excerpt: INM-755 was found to
July 29, 2022
